New research suggests the century-old BCG tuberculosis vaccine may also reduce Alzheimer’s disease risk. Originally developed against TB by Calmette and Guérin and proven highly effective, this vaccine now appears to have broad immunotherapeutic benefits. Clinical trials have demonstrated its potential in lowering Alzheimer’s and dementia risks, with studies indicating a 20-45% decrease in older patients with bladder cancer. Studies call for more research to validate these promising results, given Alzheimer’s growing prevalence and economic impact.
New results from a phase 2A clinical trial show that the new Alzheimer’s disease vaccine from Vaxxinity has promising results.
This article discusses the list of vaccine candidates, along with clinical trials, for Alzheimer’s disease in 2023.
The pharmaceutical company AC Immune SA has received FDA clearance to proceed with phase 1 and 2 clinical trials for its anti-amyloid beta vaccine for the treatment of Alzheimer’s disease. If the results of the clinical trial are positive, this… Read More »Alzheimer’s disease vaccine beginning clinical trials